INC Research Holdings, Inc. (SYNH)
(Delayed Data from NSDQ)
$47.27 USD
+0.56 (1.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.27 USD
+0.56 (1.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Syneos Health (SYNH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 9.68% and 2.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syneos Health Launches Initiative for COVID-19 Patients
by Zacks Equity Research
The primary aim of this initiative by Syneos Health (SYNH) is to address the predicted ventilator deficiency in the wake of the coronavirus pandemic.
Syneos Health (SYNH) Down 49.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syneos Health Grows on New Alliances Amid Regulatory Upheavals
by Zacks Equity Research
Syneos Health's (SYNH) new partnerships with AiCure and Indegene Omnipresence seem strategic at the moment.
Here's Why You Should Hold Syneos Health in Your Portfolio Now
by Zacks Equity Research
Syneos Health (SYNH) enjoys high investor confidence on solid prospects.
Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
We are upbeat about the strong year-over-year revenue growth in the Clinical Solutions segment of Syneos Health (SYNH) in Q4.
5 Best Value Picks to Grab on Discounted PEG
by Urmimala Biswas
Value investors with varied risk appetite are unlikely to consider price/earnings to growth (PEG) ratio among a number of other popular metrics.
Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Syneos Health (SYNH) gains from several positive developments.
SYNH vs. HMSY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SYNH vs. HMSY: Which Stock Is the Better Value Option?
Is Syneos Health (SYNH) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Syneos Health Collaborates with AiCure for Patient Engagement
by Zacks Equity Research
Syneos Health (SYNH) aims to optimize patient engagement and trial success by partnering with AiCure.
3 Reasons Why Growth Investors Shouldn't Overlook Syneos Health (SYNH)
by Zacks Equity Research
Syneos Health (SYNH) could produce exceptional returns because of its solid growth attributes.
SYNH vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SYNH vs. OMCL: Which Stock Is the Better Value Option?
Syneos Health (SYNH) Tops Q3 Earnings Estimates, Ups EPS View
by Zacks Equity Research
Syneos Health (SYNH) exhibits robust topline performance in the third quarter, backed by strong segmental growth.
Syneos Health (SYNH) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 4.82% and -0.44%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ResMed's (RMD) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) registers growth at CER across its key operating segments in Q1.
Integra LifeSciences' (IART) Earnings Top Estimates in Q3
by Zacks Equity Research
We are upbeat about the year-over-year revenue growth in Integra LifeSciences' (IART) Codman Specialty Surgical segment.
Syneos Health (SYNH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Beats on Q3 Earnings, Ups EPS View
by Zacks Equity Research
Edwards Lifesciences (EW) reports strong Q3 sales on the recent FDA indication expansion of SAPIEN 3 and SAPIEN 3 Ultra systems.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q4
by Zacks Equity Research
Varian (VAR) gains from core Oncology segment's solid contribution in fiscal Q4.
Align Technology (ALGN) Beats on Q3 Earnings, Margins Fall
by Zacks Equity Research
We are upbeat about Align Technology (ALGN) witnessing continued momentum in Invisalign volumes across all geographies
Boston Scientific (BSX) Beats on Q3 Earnings, Tapers EPS View
by Zacks Equity Research
Boston Scientific (BSX) is making an all-out effort to solidify its core businesses and invest in the new technologies as well as the global markets. This reflects on the sales uptick in Q3.
Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance
by Zacks Equity Research
We are encouraged that three out of Thermo Fisher's (TMO) four business segments have registered strong year-over-year revenue growth in Q3.
SYNH vs. CERN: Which Stock Is the Better Value Option?
by Zacks Equity Research
SYNH vs. CERN: Which Stock Is the Better Value Option?